MSB Trading 2020 - a new dawn, page-11378

EAP results in April were in line with other stem cell trials around the world. It works

Phase 3 trial in record time , paid by NIH , tick

30 % readout , DSMB says continue
SI says “ flew through “.

Reg says that means zero deaths

45% readout, DSMB says continue
Trial adjusted - No excessive BMI patients

Reg says - unexpected deaths

60% readout imminent
SI says meet our new Swedish mate Nov
FDA says fast track approved

Reg says - That’s political arse covering, marketing and strategic partnerships in place.

Reg

The bottom line is that the drug did work. My guess is overwhelming efficacy with 15% death against 65% death rate. A whopping 50% improvement over current approved standard of care.